Pennsylvania Medical Marijuana Program Surpasses $9.1 Billion in Sales
- Pennsylvania’s medical marijuana program has exceeded $9.1 billion in sales since its inception, with over 1.1 million patient registrations and 438,244 active patient certifications.
- The state currently supports 1,920 approved practitioners and 192 operational dispensaries, maintaining monthly sales above $140 million, with a record $160 million in December 2025.
- There has been a significant drop in dry leaf marijuana prices from $14.90 to $7.60 per gram retail, and from $10.65 to $2.85 per gram wholesale between early 2021 and early 2026.
- Since legalizing medical marijuana in 2016, Pennsylvania has allowed patient access through licensed dispensaries, while lawmakers continue to debate broader reforms including adult-use legalization.
Pennsylvania’s medical marijuana program has surpassed $9.1 billion in sales since its launch, according to data presented recently to the state’s Medical Marijuana Advisory Board.
The report shows the state now has 438,244 active patient certifications, 1,920 approved practitioners and 192 operational dispensaries. The program has also recorded 1,109,727 patient registrations since launching.
Sales have remained strong despite continued price compression. Monthly dispensary sales have generally stayed above $140 million in recent months, with January and February 2026 both outperforming the same months in 2025. The program’s strongest sales month was December 2025, when sales reached roughly $160 million.
The report also highlights a steep decline in dry leaf prices over the past several years. Retail prices fell from $14.90 per gram in early 2021 to $7.60 per gram by early 2026, while wholesale prices dropped from $10.65 per gram to $2.85 over the same period.
Pennsylvania legalized medical marijuana in 2016, with the state’s first dispensary sales beginning in February 2018. The program allows patients with qualifying conditions to access marijuana products through licensed dispensaries, but lawmakers have continued to consider broader reforms, including adult-use legalization.